The FDA advisory committee voted to recommend the XIENCE V stent system for approval with conditions related to post-marketing study requirements and language related to dual antiplatelet therapy.

• 在上市后继续进行研究和使用双重抗血小板治疗的条件下，FDA顾问委员会投票推荐核准XIENCE V支架系统上市。